These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1959444)

  • 1. The generation of antibody combining sites containing catalytic residues.
    Shokat KM; Schultz PG
    Ciba Found Symp; 1991; 159():118-28; discussion 128-34. PubMed ID: 1959444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new strategy for the generation of catalytic antibodies.
    Shokat KM; Leumann CJ; Sugasawara R; Schultz PG
    Nature; 1989 Mar; 338(6212):269-71. PubMed ID: 2922053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large rate accelerations in antibody catalysis by strategic use of haptenic charge.
    Thorn SN; Daniels RG; Auditor MT; Hilvert D
    Nature; 1995 Jan; 373(6511):228-30. PubMed ID: 7816136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody catalysis via strategic use of haptenic charge.
    Kikuchi K; Hilvert D
    Acta Chem Scand (Cph); 1996 Apr; 50(4):333-6. PubMed ID: 8639376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of an antibody-catalysed allylic isomerization.
    Gonçalves O; Dintinger T; Lebreton J; Blanchard D; Tellier C
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):691-8. PubMed ID: 10698695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Site-Directed Chemical Mutations on Abzymes: Large Rate Accelerations in the Catalysis by Exchanging the Functionalized Small Nonprotein Components.
    Ishikawa F; Shirahashi M; Hayakawa H; Yamaguchi A; Hirokawa T; Tsumuraya T; Fujii I
    ACS Chem Biol; 2016 Oct; 11(10):2803-2811. PubMed ID: 27552288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New strategies for the design of catalytic antibodies.
    Janda KD
    Biotechnol Prog; 1990; 6(3):178-81. PubMed ID: 1366610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that the mechanism of antibody-catalysed hydrolysis of arylcarbamates can be determined by the structure of the immunogen used to elicit the catalytic antibody.
    Boucher G; Said B; Ostler EL; Resmini M; Brocklehurst K; Gallacher G
    Biochem J; 2007 Feb; 401(3):721-6. PubMed ID: 17020536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of catalytic antibody repertoire in autoimmune mice.
    Nishi Y
    J Immunol Methods; 2002 Nov; 269(1-2):213-33. PubMed ID: 12379363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural evidence for a programmed general base in the active site of a catalytic antibody.
    Golinelli-Pimpaneau B; Goncalves O; Dintinger T; Blanchard D; Knossow M; Tellier C
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):9892-5. PubMed ID: 10963661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyridoxal-5'-phosphate-dependent catalytic antibodies.
    Gramatikova S; Mouratou B; Stetefeld J; Mehta PK; Christen P
    J Immunol Methods; 2002 Nov; 269(1-2):99-110. PubMed ID: 12379355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for antibody catalysis of a disfavored ring closure reaction.
    Gruber K; Zhou B; Houk KN; Lerner RA; Shevlin CG; Wilson IA
    Biochemistry; 1999 Jun; 38(22):7062-74. PubMed ID: 10353817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short synthetic peptides exploited for reliable and specific targeting of antibodies to the C-termini of cytochrome P450 enzymes.
    Edwards RJ; Singleton AM; Murray BP; Davies DS; Boobis AR
    Biochem Pharmacol; 1995 Jan; 49(1):39-47. PubMed ID: 7840781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for antibody catalysis of a cationic cyclization reaction.
    Zhu X; Heine A; Monnat F; Houk KN; Janda KD; Wilson IA
    J Mol Biol; 2003 May; 329(1):69-83. PubMed ID: 12742019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The scope of antibody catalysis.
    Jacobsen JR; Schultz PG
    Curr Opin Struct Biol; 1995 Dec; 5(6):818-24. PubMed ID: 8749371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of covalent binding antibodies.
    Armentano F; Knight T; Makker S; Tramontano A
    Immunol Lett; 2006 Feb; 103(1):51-7. PubMed ID: 16297987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural insights into the evolution of an antibody combining site.
    Wedemayer GJ; Patten PA; Wang LH; Schultz PG; Stevens RC
    Science; 1997 Jun; 276(5319):1665-9. PubMed ID: 9180069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanded transition state analogues.
    Blackburn GM; Kingsbury G; Jayaweera S; Burton DR
    Ciba Found Symp; 1991; 159():211-22; discussion 222-6. PubMed ID: 1959449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An investigation of antibody acyl hydrolysis catalysis using a large set of related haptens.
    Odenbaugh AL; Helms ED; Iverson BL
    Bioorg Med Chem; 2000 Feb; 8(2):413-26. PubMed ID: 10722164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid sequences and hapten binding of catalytic and noncatalytic antibodies against N(alpha)-(5'-phosphopyridoxyl)-L-lysine.
    Mouratou B; Gramatikova S; Kunz B; Christen P
    Mol Immunol; 2000 Aug; 37(11):633-40. PubMed ID: 11164891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.